In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Diabetic status influences the effect of pro-inflammatory interleukin-1 genotypes on lipoprotein(a) mediated risk of coronary artery disease and cardiovascular events

Session Poster session 2

Speaker Aris Bechlioulis

Congress : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease - Pathophysiology and Mechanisms
  • Session type : Poster Session
  • FP Number : P1761

Authors : KK Naka (Ioannina,GR), A Bechlioulis (Ioannina,GR), L Douchette-Stamm (Waltham, MA,US), L Wilkins (Waltham, MA,US), A Marini (Ioannina,GR), M Bougiakli (Ioannina,GR), S Giannitsi (Ioannina,GR), J Rogus (Waltham, MA,US), K Kornman (Waltham, MA,US), JL Witztum (La Jolla, CA,US), S Tsimikas (La Jolla, CA,US), LK Michalis (Ioannina,GR)

K.K. Naka1 , A. Bechlioulis2 , L. Douchette-Stamm3 , L. Wilkins3 , A. Marini2 , M. Bougiakli2 , S. Giannitsi2 , J. Rogus3 , K. Kornman3 , J.L. Witztum4 , S. Tsimikas4 , L.K. Michalis1 , 1University of Ioannina, 2nd Department of Cardiology and Michaelidion Cardiac Center - Ioannina - Greece , 2University of Ioannina, Michaelidion Cardiac Center - Ioannina - Greece , 3Interleukin Genetics, Inc. - Waltham, MA - United States of America , 4University of California San Diego, Department of Medicine - La Jolla, CA - United States of America ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 390

Background: Pro-inflammatory Interleukin-1 (IL-1) genotypes have been previously shown to affect the risk of angiographic coronary artery disease (CAD) and cardiovascular events mediated by lipoprotein(a) [Lp(a)] in non-diabetic patients.

Purpose: We investigated whether type 2 diabetes mellitus (DM) may alter the effect of this genotype on the relation of Lp(a) with CAD presence and cardiovascular events.

Methods: We enrolled 1,084 patients (mean age 65 years, 70% males, 44% DM) undergoing diagnostic coronary angiography. Plasma Lp(a) levels were measured. The composite genotype IL-1(+) was defined by 3 single-nucleotide polymorphisms in the IL-1 gene cluster. Angiographic CAD was diagnosed as a >50% stenosis in a coronary artery. Cardiovascular death, non-fatal myocardial infarction and stroke (n=77) were assessed after a median follow-up of 43 months (range 24–68).

Results: Angiographic CAD was more prevalent in DM vs non-DM patients (OR 1.73, p<0.001) while there was no significant difference in the occurrence of events at follow-up in DM vs non-DM (HR 1.10, p=0.645). In the non-DM group, the highest Lp(a) quartile was associated with a higher risk for CAD compared with the lowest quartile in IL-1(+) (OR 1.87, p=0.032); this effect was further accentuated in younger (≤60 years) patients (OR 2.90, p=0.036). In multivariate analysis, Lp(a) levels remained an independent predictor of CAD in younger IL-1(+) patients (OR 1.35, p=0.016) after adjustment of for various confounders. Non-DM IL-1(+) patients with high Lp(a) had worse event-free survival compared with other groups (HR 3.47, p<0.001). After adjustment for risk factors, higher Lp(a) (HR 1.29 per doubling, p<0.001) and IL-1(+) (HR 2.03, p=0.038) were independent predictors of adverse prognosis in non-DM patients. In contrast, no association of IL-1(+) status and Lp(a) was found with CAD presence or cardiovascular events in DM patients.

Conclusions: In non-DM patients, IL-1 genotype influences the Lp(a)-mediated risk for CAD presence mainly in younger patients referred for angiography. Both Lp(a) levels and IL-1 genotype status independently and cumulatively predict cardiovascular events in non-DM patients. The lack of an IL-1/Lp(a) association in patients with DM needs to be further evaluated in future studies.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are